Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 392 |
| Referral date | 01 October 2000 |
| Topic area |
|
Provisional Schedule
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | Fraser Woodward |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 November 2022 | Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 November 2022 | Discontinued. Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual